Quarterly report pursuant to Section 13 or 15(d)

Commitments and contingencies (Details Narrative)

v3.21.2
Commitments and contingencies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Sep. 06, 2018
Mar. 17, 2017
Jun. 30, 2020
Jun. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Monthly payments       $ 1,448
Law suit filing date       May 28, 2019
Description on trial dispute resolution       On November 13, 2019, G Farma filed a Cross-Complaint for declaratory relief and breach of contract relating to the consulting agreement between Mentor and G Farma. The Company filed an answer on December 6, 2019, denying each and every allegation of the Cross-Complaint and intends to vigorously defend itself in this matter. Mentor is currently in the process of preparing for trial on the remaining causes of action against the G Farma Entities and their guarantors. Trial is currently scheduled to commence on September 20, 2021.
Litigation award and collection of lease payments       $ 1,290,174
G Farma Labs Limited [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Description of equity interests issuable to acquire the entity. On March 4, 2019, Addendum VIII increased the G Farma Equity Entities’ equity interest to which Mentor is immediately entitled to 3.843%, and added Goya Ventures, LLC as a G Farma Equity Entity.      
G Farma Labs Limited [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sale of recovered equipment     $ 495,967  
Loss contingency receivable proceeds     222,031  
Remaining sale of recovered equipment     126,703  
Remaining loss contingency receivable proceeds     $ 27,450  
Loss contingency damages awarded value       $ 1,166,570
Notes Purchase Agreement [Member] | G Farma Labs Limited [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Purchase of secured promissory notes   $ 500,000    
Increased aggregate principal face amount   1,100,000    
Notes Purchase Agreement [Member] | G Farma Labs Limited [Member] | Secured Promissory Notes [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Monthly payments   10,239    
Ballon payments on notes   $ 894,172    
Equity Purchase and Issuance Agreement [Member] | G Farma Labs Limited [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Equal interest percentage 375.00%